EN E-000307/2021 Answer given by Ms Gabriel on behalf of the European Commission (31.3.2021)

Personalised Medicine will, indeed, be of great importance in projects funded under Horizon Europe<sup>1</sup> in the Health Cluster and for relevant projects funded in the European Research Council<sup>2</sup>, the Marie Skłodowska-Curie actions<sup>3</sup> and the European Innovation Council<sup>4</sup>. Many fields will be open for proposals, without specifying the diseases to be addressed, so, in principle, also open for asthma and allergy, including also co-morbidities involving those diseases.

In addition, the Commission is working on setting up a European Partnership for Personalised Medicine<sup>5</sup>, in collaboration with the Member States (MS) and regions. It is scheduled to start in the second half of 2023. It will address priorities for research and innovation in personalised medicine and its implementation in the healthcare sector, and co-fund projects between the MS and the Commission.

Currently, the Commission is involved in the International Consortium for Personalised Medicine, that discusses research priorities between the Member States, and in the ERA-PerMed network<sup>6</sup> that funds projects in the area.

Also, several projects belonging to the European Human Exposome cluster focus on identifying risk factors for respiratory and immune-related diseases (including allergies and asthma) and contribute to personalised exposure assessments. Future topics in Horizon Europe will address environment and health, where allergy and asthma can be included.

Personalised Medicine has mainly focused on chronic diseases, including cancer, but the COVID-19 pandemic has demonstrated that individual responses to infections vary significantly. Consequently, there will be an interest in investigating further co-morbidities linked to infections, such as asthma and allergic responses.

<sup>&</sup>lt;sup>1</sup> https://ec.europa.eu/info/horizon-europe\_en

<sup>&</sup>lt;sup>2</sup> https://erc.europa.eu/

<sup>&</sup>lt;sup>3</sup> https://ec.europa.eu/research/mariecurieactions/node\_en

<sup>&</sup>lt;sup>4</sup> https://ec.europa.eu/research/eic/index.cfm

<sup>&</sup>lt;sup>5</sup> https://www.icpermed.eu/

<sup>&</sup>lt;sup>6</sup> https://www.era-learn.eu/network-information/networks/era-permed